An international pharmaceutical campaign group is urging the European Medicines Agency to tighten its rules that require patient and consumer bodies that work with the agency to disclose any corporate funding they receive. This follows the group’s research findings that two thirds of the bodies advising the agency received “partial or significant” funding from pharmaceutical manufacturers or industry associations.

At the same time, fewer than half of these bodies met the agency’s own financial reporting guidelines, the report by Health Action International Europe shows.

The campaign group investigated the funding and disclosure of 23 organisations that were eligible to work …